Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes

17 Jan 2018

• By Derrick Gingery

FDA Advisory Committee Feature image

Related Content

Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte

08 Jan 2018

Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee

10 Jan 2018

Lipocine Testosterone Therapy Faces Safety, Stopping Criteria Concerns At US FDA Advisory Cmte

09 Jan 2018

Lipocine's Tlando Falls Short At US FDA Advisory Cmte Over Blood Pressure Concerns

11 Jan 2018

Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval

17 Jan 2018

Related Companies

Clarus Therapeutics Holdings, Inc.

Lipocine Inc.

Additional Topics

United States Advisory Committees Regulation FDA Gynecology & Urology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.